Search

Discover some of the latest innovations in chemotherapy for breast cancer.

… Thursday, October 10, 2019 Summary Chemotherapy has come a long way in treating breast cancer. Learn about some of the latest advances.   Chemotherapy has been a mainstay of cancer treatment since the 1940s, and it is still evolving to this day. For people with breast cancer , treatment innovations take

Learn how tiny sensors made of nanotubes could serve as implantable devices that offer a noninvasive way to monitor cancer and its treatments.

… Tuesday, March 14, 2017 Summary It is difficult to monitor diseases like cancer without repeated biopsies and imaging scans. A solution could be offered by the field of nanotechnology , in the form of tiny sensors made up of carbon nanotubes. The sensors could be implanted under the skin, and a small

Dr. Bob Li will present registrational phase II data from the first-ever trial of a drug that blocks cancer gene KRAS.

… Friday, January 29, 2021 International scientists, researchers, physicians and patient advocates in the field of lung cancer and thoracic malignancies will tune in January 28-31, 2021, for the 2020 World Conference on Lung Cancer (WCLC) hosted by the International Association for the Study of Lung Cancer

Learning more about epithelioid hemangioendothelioma (EHE) is an ongoing mission of MSK’s sarcoma research.

… Wednesday, July 21, 2021 Memorial Sloan Kettering has been a leader in the care of sarcoma patients for decades, treating about 70% of the cases in the New York City tri-state area. A disease largely affecting young people, sarcoma is a rare cancer of the bones and soft tissues with more than 50 subtypes

Memorial Sloan Kettering Cancer Center (MSK) announced today that the U.S. Food and Drug Administration (FDA) has approved the oral MEK inhibitor drug cobimetinib (COTELLIC®) for the treatment of adult patients with the family of blood diseases know as histiocytic neoplasms (HN). These diseases include: Erdheim-Chester Disease, Rosai-Dorfman, and Langerhans Histiocytosis. Cobimetinib is an oral inhibitor of MEK1 and MEK2 currently approved to treat melanoma.

… Tuesday, November 1, 2022 Memorial Sloan Kettering Cancer Center (MSK) announced today that the U.S. Food and Drug Administration (FDA) has approved the oral MEK inhibitor drug cobimetinib (Cotellic ® ) for the treatment of adult patients with the family of blood diseases known as histiocytic neoplasms

A pivotal international study published in the New England Journal of Medicine and led in part by José Baselga, MD, PhD, Physician-in-Chief at Memorial Sloan Kettering Cancer Center (MSK), offers proof of better treatment options for patients with HER2-positive early breast cancer. The new international research found that the drug pertuzumab (Perjeta®) significantly improved invasive-disease-free survival (IDFS) in patients with operable HER2-positive breast cancer when added to trastuzumab (Herceptin®) and chemotherapy. The findings of this study were presented at the American Society of Clinical Oncology annual meeting today in Chicago.

… Monday, June 5, 2017 A pivotal international study published in the New England Journal of Medicine and led in part by José Baselga, MD, PhD , Physician-in-Chief at Memorial Sloan Kettering Cancer Center (MSK), offers proof of better treatment options for patients with HER2-positive early breast cancer

MSK introduced its first new creative campaign in nearly two decades. The creative platform and campaign elements were developed and produced by MSK’s creative agency of record, Pereira & O’Dell New York.

… Tuesday, September 2, 2014 Memorial Sloan Kettering Cancer Center today introduced its first new creative campaign in nearly two decades: More Science. Less Fear. The creative platform and campaign elements were developed and produced by MSK’s creative agency of record, Pereira & O’Dell New York. MSK

Four summer students -- Jeannie Camarillo, Emily Grzybowski, Nathaniel Kim, and Daniel Triner -- were named 2010 Rubin and Sarah Shaps Scholars.

… Thursday, September 1, 2011 Four summer students are named Rubin and Sarah Shaps Scholars each summer. Students are selected on the basis of their outstanding undergraduate credentials and their performance in our summer program. Jeannie Camarillo, a junior majoring in physiology at the University of

MSK physicians and scientists are involved in notable research to be presented at the meeting and are available to comment on a variety of topics within leukemia, lymphoma, and multiple myeloma.

… Friday, December 4, 2020 Thousands of oncology experts from around the world will tune in December 5-8, 2020 for The American Society of Hematology’s (ASH) Annual Meeting and Exposition . For more than 60 years, the (ASH) Annual Meeting and Exposition has been the world’s most comprehensive hematology

MSK investigators report a new tool that may help them determine the origin of some metastatic tumors, potentially leading to better targeted treatments.

… Thursday, November 14, 2019 Summary Despite many advances in diagnostic technologies, the original site of some cancers will never be found. A new tool may help. Experts estimate that between 2 and 5% of all cancers are classified as cancer of unknown primary (CUP) , also called occult primary cancer